Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 394 | 84 | 307 |
| Samples | 377 | 80 | 295 |
| Peptides | 274 | 55 | 228 |
Function
CAPN11 · Calpain 11
Calpains constitute a family of intracellular calcium-dependent cysteine proteases. There are eight members in this superfamily. They consist of a variable 80 kDa subunit and an invariant 30 kDa subunit. This calpain protein appears to have protease activity and calcium-binding ability. A similar mouse protein may play a functional role in spermatogenesis and in the regulation of calcium-dependent signal transduction events during meiosis. [provided by RefSeq, Dec 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 273 amino-acid changes on canonical ENST00000398776 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CAPN11 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CAPN11 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Melanoma | 10/210 5% | 62/1899 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Endometrial Carcinoma | 4/42 10% | 12/612 2% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 20/1390 1% |
| Colorectal Carcinoma | 8/143 6% | 32/3239 1% |
| Plasma Cell Myeloma | 3/44 7% | 1/305 0% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Cervical Carcinoma | 2/35 6% | 3/422 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 8/752 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Other Solid Cancers | 1/94 1% | 14/1515 1% |
| Other Sarcomas | 2/69 3% | 5/699 1% |
| Gastric Carcinoma | 1/74 1% | 16/1809 1% |
| Neuroendocrine Tumour | 6/154 4% | 0/577 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 13/1592 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Bladder Carcinoma | 0/58 0% | 7/956 1% |
| Breast Carcinoma | 10/144 7% | 13/3264 0% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Pancreatic Carcinoma | 3/89 3% | 7/1611 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 8/2550 0% |
| Glioma | 1/52 2% | 9/2127 0% |
Mutation Distribution
Where CAPN11 is mutated · all tissues, split by cell line vs tissue
How many mutations in CAPN11 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 394 mutations in CAPN11
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|